RedHill Biopharma Ltd.RDHLNASDAQ
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank44
Year-over-Year Change
Year-over-year revenue growth rate
Latest
0.00%
↓ 100% vs avg
Percentile
P44
Within normal range
Streak
1 qtr
Consecutive growthDecelerating
Average
44.60%
Historical baseline
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | -25.44% |
| Q4 2024 | 0.00% |
| Q3 2024 | 112.71% |
| Q2 2024 | 0.00% |
| Q1 2024 | 126.61% |
| Q4 2023 | 0.00% |
| Q3 2023 | -68.40% |
| Q2 2023 | -50.10% |
| Q1 2023 | -71.88% |
| Q4 2022 | -27.09% |
| Q3 2022 | -4.33% |
| Q2 2022 | 40.00% |
| Q1 2022 | -40.63% |
| Q4 2021 | 2.14% |
| Q3 2021 | 0.50% |
| Q2 2021 | 4.51% |
| Q1 2021 | -4.13% |
| Q4 2020 | 2.47% |
| Q3 2020 | 0.21% |
| Q2 2020 | 1879.07% |
| Q1 2020 | -33.58% |
| Q4 2019 | 13.49% |
| Q3 2019 | -10.36% |
| Q2 2019 | -10.02% |
| Q1 2019 | 27.81% |
| Q4 2018 | -38.40% |
| Q3 2018 | -6.13% |
| Q2 2018 | -3.89% |
| Q1 2018 | 22.19% |
| Q4 2017 | 31.39% |
| Q3 2017 | 215.32% |
| Q2 2017 | 0.00% |
| Q1 2017 | -100.00% |
| Q4 2016 | 0.00% |
| Q3 2016 | -100.00% |
| Q2 2016 | 0.00% |
| Q1 2016 | 0.00% |
| Q4 2015 | -100.00% |
| Q3 2015 | 0.00% |